Alkem launches pertuzumab biosimilar ‘Pertuza’ for treatment of HER2-positive breast cancer

Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab

FDA responds to evidence of possible association between autism and acetaminophen use during pregnancy

Agency initiates safety label change and notifies physicians of possible link

Akums demonstrates clinical versatility of Lacosamide in epilepsy care

Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.

CuraTeQ Biologics completes Phase 3 clinical study for Denosumab biosimilar

Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints

Biocon Biologics receives FDA approval for Bosaya and Aukelso biosimilars

FDA grants breakthrough therapy designation to R-DXd for platinum-resistant ovarian and related cancers

Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo

GAIASO appoints Dr. Tracey Brown as CEO

Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,

Kerala to host Ayush Mission workshop on “IT solutions in the Ayush sector”

The discussions are expected to pave the way for the creation of a consolidated national knowledge-sharing platform on IT-enabled Ayush services,

Apollo Hospitals acquires IFC’s 3% share in Apollo Health and Lifestyle for Rs. 1,254 Cr

AHLL will become a 100% subsidiary of AHEL with 99.42% held by AHEL and balance in the ESOP pool

FDA approves sBLA for Takeda's Vonvendi for Von Willebrand disease

Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD